Vogelxo

Vogelxo^® is a prescription topical testosterone gel used for testosterone replacement therapy in adult men with hypogonadism, a condition where the body does not produce enough of the hormone. 

Vogelxo helps restore normal testosterone levels. It is applied once daily to clean, dry skin on the shoulders and/or upper arms. Dosing may vary based on the person’s testosterone levels and response to the medication.

Side effects are generally mild, but in rare cases, Vogelxo may be associated with more serious adverse effects such as elevated red blood cell count or worsening of underlying prostate conditions. Vogelxo also poses potential harm to others via secondary exposure, especially women and children. Proper application techniques and hygiene are essential in order to reduce these risks. 

Regular monitoring by a healthcare provider is necessary for ensuring safe and effective use of this medication.

Vogelxo (testosterone) is indicated for:

• Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone:

  • Primary hypogonadism (congenital or acquired)

  • Hypogonadotropic hypogonadism (congenital or acquired)

Androgen

Most common adverse reactions (incidence ≥2% of the testosterone gel patients and greater than placebo) are:

• Application site reactions

• Increased hematocrit

The price of Vogelxo may vary depending on the dosage, quantity, where you buy it, and your insurance plan. The average retail price of Vogelxo is about $600 for two pumps, but coupons and discount cards may be available to bring down the price to as low as about $200. Generic Vogelxo (testosterone gel) costs about $430 for a month’s supply, but coupons are available to bring down the price as low as about $92. Health insurance may cover all or some of the cost of this medication.

• Men with known carcinoma of the breast or known or suspected carcinoma of the prostate

• Women who are pregnant. Testosterone may cause fetal harm

• Drug interactions: Androgens may decrease blood glucose and therefore may decrease insulin requirements in diabetic patients, changes in anticoagulant activity may be seen with androgens, use of testosterone with corticosteroids may result in increased fluid retention

• Monitor patients with benign prostatic hyperplasia (BPH) for worsening of signs and symptoms of BPH

• Avoid unintentional exposure of women or children to Vogelxo. Secondary exposure to testosterone can produce signs of virilization

• Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), have been reported in patients using testosterone products

• Some postmarketing studies have shown an increased risk of heart attack and stroke associated with use of testosterone replacement therapy

• Exogenous administration of androgens may lead to azoospermia

• Edema, with or without congestive heart failure, may be a complication in patients with preexisting cardiac, renal, or hepatic disease

• Sleep apnea may occur in those with risk factors

• Monitor prostate specific antigen (PSA), hematocrit, and lipid concentrations periodically

• Vogelxo is flammable until dry

WARNING: SECONDARY EXPOSURE TO TESTOSTERONE

Virilization has been reported in children who were secondarily exposed to testosterone gel.

Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel.

Healthcare providers should advise patients to strictly adhere to recommended instructions for use.

*This information is from the label for brand name Vogelxo^®. See the Full Prescribing Information for more complete information. Testosterone, the active ingredient in Vogelxo, may also be the active ingredient in other medications, and this information may not be accurate for all medications that include the active ingredient testosterone.